OvaScience (OVAS) Misses Q1 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/29/2026
- Wall St indexes climb as US, Iran halt attacks; Comcast surges on spin-off plan
- Tech funds suffer record outflows as investors trim equity positions
- Comcast shares surge 23% on blockbuster plan to spin off NBCUniversal and Sky
- New leader board: Citi refreshes AI compute semiconductor picks
- Martin Marietta confirms $13.5B deal for Lhoist North America
- Needham Starts NeoVolta (NEOV) at Buy
- Personalis, Inc. (PSNL) and Tempus (TEM) Expand Collaboration
- Micron ships 245TB data center SSD, claims world's highest capacity
- Strategy stock jumps 7% as firm shifts to active capital management
- Triller to acquire SpaceX exposure as treasury asset via fund structure
OvaScience Reports First Quarter 2016 Financial Results
May 5, 2016 4:00 PM EDTAUGMENT treatment gains traction in growing fertility market and Company expands access internationally
New research supports AUGMENT and pipeline treatments
WALTHAM, Mass.--(BUSINESS WIRE)-- OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported its first quarter 2016 financial results and highlighted recent accomplishments.
OvaScience is currently focused on building our operational platform to support the expansion of the AUGMENT treatment. We are focusing our AUGMENT commercial efforts to target Canada and Japan as our... More
